| abstract |
The present invention relates to a method for temporal administration of an EDA agonist, in particular EDI200, correlated with an optimal therapeutic response window required for the formation of any EDA-dependent structure, such as ectoderm appendages. The use of the described methods allows the design of targeted therapeutic dosage and administration regimens to correct or alter genetic phenotypes, particularly abnormal phenotypes associated with XLHED. |